A recent collaboration involving Merck, Amgen, Deloitte, and QuEra Computing has explored a novel approach—quantum reservoir computing (QRC)—to better handle these small-data scenarios for molecular property prediction. The success of this project not only illuminates the potential of QRC in drug discovery but also suggests broader applications in time-series analysis, missing-data imputation, and biomarker detection.
The post Quantum Case Study: Merck, Amgen, Deloitte, and QuEra Tackle Clinical Trial Prediction appeared first on HPCwire.
